Cargando…

Cerebrospinal Fluid Penetrance of Daratumumab in Leptomeningeal Multiple Myeloma

Detalles Bibliográficos
Autores principales:	Zajec, Marina, Frerichs, Kristine A., van Duijn, Martijn M., Nijhof, Inger S., Stege, Claudia A.M., Avet-Loiseau, Hervé, Luider, Theo M., de Rijke, Yolanda B., Jacobs, Joannes F.M., van de Donk, Niels W.C.J.
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Wolters Kluwer Health 2020
Materias:	Letter
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7448363/ https://www.ncbi.nlm.nih.gov/pubmed/32904033 http://dx.doi.org/10.1097/HS9.0000000000000413

Ejemplares similares

Cytomegalovirus Reactivation in a Patient With Extensively Pretreated Multiple Myeloma During Daratumumab Treatment
por: Frerichs, Kristine A., et al.
Publicado: (2019)

CD38-targeted therapy with daratumumab reduces autoantibody levels in multiple myeloma patients
por: Frerichs, Kristine A., et al.
Publicado: (2019)

Deep immune profiling of patients treated with lenalidomide and dexamethasone with or without daratumumab
por: Casneuf, Tineke, et al.
Publicado: (2020)

Trogocytosis represents a novel mechanism of action of daratumumab in multiple myeloma
por: Krejcik, Jakub, et al.
Publicado: (2018)

Efficacy and Safety of Durvalumab Combined with Daratumumab in Daratumumab-Refractory Multiple Myeloma Patients
por: Frerichs, Kristine A., et al.
Publicado: (2021)

Efficacy and safety of daratumumab combined with all-trans retinoic acid in relapsed/refractory multiple myeloma
por: Frerichs, Kristine A., et al.
Publicado: (2021)

Retrospective Longitudinal Monitoring of Multiple Myeloma Patients by Mass Spectrometry Using Archived Serum Protein Electrophoresis Gels and De Novo Sequence Analysis
por: Noori, Somayya, et al.
Publicado: (2022)

T-cell redirecting bispecific antibodies targeting BCMA for the treatment of multiple myeloma
por: Verkleij, Christie P.M., et al.
Publicado: (2020)

P37 MULTIPLE MYELOMA MONITORING FROM ARCHIVED SERUM PROTEIN ELECTROPHORESIS GELS BY MASS SPECTROMETRY AND DE NOVO SEQUENCING
por: Noori, S., et al.
Publicado: (2023)

High‐Parameter Mass Cytometry Evaluation of Relapsed/Refractory Multiple Myeloma Patients Treated with Daratumumab Demonstrates Immune Modulation as a Novel Mechanism of Action
por: Adams, Homer C., et al.
Publicado: (2018)

PB2132: EXCALIBER-RRMM: A PHASE 3, TWO-STAGE STUDY OF IBERDOMIDE, DARATUMUMAB, AND DEXAMETHASONE VERSUS DARATUMUMAB, BORTEZOMIB, AND DEXAMETHASONE IN PATIENTS WITH RELAPSED/REFRACTORY MULTIPLE MYELOMA
por: Lonial, Sagar, et al.
Publicado: (2023)

Ixazomib, daratumumab and low-dose dexamethasone in intermediate-fit patients with newly diagnosed multiple myeloma: an open-label phase 2 trial
por: Groen, Kaz, et al.
Publicado: (2023)

Resistance Mechanisms towards CD38−Directed Antibody Therapy in Multiple Myeloma
por: Franssen, Laurens E., et al.
Publicado: (2020)

NK Cell Phenotype Is Associated With Response and Resistance to Daratumumab in Relapsed/Refractory Multiple Myeloma
por: Verkleij, Christie P.M., et al.
Publicado: (2023)

Carfilzomib for relapsed and refractory multiple myeloma
por: Groen, K, et al.
Publicado: (2019)

P877: IXAZOMIB DARATUMUMAB AND LOW-DOSE DEXAMETHASONE IN INTERMEDIATE-FIT PATIENTS WITH NEWLY DIAGNOSED MULTIPLE MYELOMA; RESULTS OF THE INDUCTION AND MAINTENANCE TREATMENT OF THE PHASE II HOVON 143 STUDY
por: Groen, Kaz, et al.
Publicado: (2023)

Leptomeningeal Metastasis: The Role of Cerebrospinal Fluid Diagnostics
por: Bönig, Lena, et al.
Publicado: (2019)

P13 IXAZOMIB, DARATUMUMAB AND LOW-DOSE DEXAMETHASONE IN INTERMEDIATE-FIT PATIENTS WITH NEWLY DIAGNOSED MULTIPLE MYELOMA; RESULTS OF THE INDUCTION AND MAINTENANCE TREATMENT OF THE PHASE II HOVON 143 STUDY
por: Groen, K., et al.
Publicado: (2023)

P18 SKIN EXPRESSION OF P16(INK4A), A BIOMARKER FOR CELLULAR SENESCENCE, DOES NOT PREDICT FRAILTY OR TREATMENT OUTCOME IN NEWLY DIAGNOSED MULTIPLE MYELOMA
por: Smits, F., et al.
Publicado: (2023)

A Case Report of Leptomeningeal Myelomatosis and Rapid Improvement with Regimen Consisting of Daratumumab, Pomalidomide, Vincristine, Procarbazine, and Dexamethasone
por: Kuan, Jew Win, et al.
Publicado: (2022)

Immunohistochemical analysis of the cerebrospinal fluid for carcinomatous and lymphomatous leptomeningitis.
por: Hovestadt, A., et al.
Publicado: (1990)

P906: IXAZOMIB, DARATUMUMAB AND LOW DOSE DEXAMETHASONE IN FRAIL PATIENTS WITH NEWLY DIAGNOSED MULTIPLE MYELOMA (NDMM): RESULTS OF THE MAINTENANCE TREATMENT OF THE PHASE II HOVON 143 STUDY
por: Groen, K., et al.
Publicado: (2022)

Measurable Residual Disease Testing in Multiple Myeloma Routine Clinical Practice: A Modified Delphi Study
por: Ramasamy, Karthik, et al.
Publicado: (2023)

Mannan-binding lectin in cerebrospinal fluid: a leptomeningeal protein
por: Reiber, Hansotto, et al.
Publicado: (2012)

Clinical outcome of cerebrospinal fluid shunts in patients with leptomeningeal carcinomatosis
por: Kim, Hye Seon, et al.
Publicado: (2019)

Genotyping of cerebrospinal fluid in lung cancer patients with leptomeningeal metastasis
por: Nie, Naifu, et al.
Publicado: (2022)

Cerebrospinal fluid metabolomic profiles can discriminate patients with leptomeningeal carcinomatosis from patients at high risk for leptomeningeal metastasis
por: Yoo, Byong Chul, et al.
Publicado: (2017)

Immunotherapy in myeloma: Why, when and how?
por: van de Donk, Niels W.C.J.
Publicado: (2018)

Current and New Therapeutic Strategies for Relapsed and Refractory Multiple Myeloma: An Update
por: Nijhof, Inger S., et al.
Publicado: (2017)

Diagnostic Value of CYFRA 21-1 in the Cerebrospinal Fluid for Leptomeningeal Metastasis
por: Zhang, Zhen, et al.
Publicado: (2017)

Detection of Leptomeningeal Disease Using Cell-Free DNA From Cerebrospinal Fluid
por: White, Michael D., et al.
Publicado: (2021)

Subcutaneous daratumumab in patients with relapsed or refractory multiple myeloma: part 2 of the open-label, multicenter, dose-escalation phase Ib study (PAVO)
por: San-Miguel, Jesus, et al.
Publicado: (2020)

S192: TALQUETAMAB (TAL) + DARATUMUMAB (DARA) IN PATIENTS (PTS) WITH RELAPSED/REFRACTORY MULTIPLE MYELOMA (RRMM): UPDATED TRIMM-2 RESULTS
por: Bahlis, Nizar J, et al.
Publicado: (2023)

Lenalidomide for the treatment of relapsed and refractory multiple myeloma
por: van de Donk, Niels WCJ, et al.
Publicado: (2012)

Cerebrospinal fluid penetration of linezolid in neurosurgical patients
por: Myrianthefs, P, et al.
Publicado: (2006)

Cerebrospinal fluid cytology findings in a case of diffuse leptomeningeal glioneuronal tumour
por: Jensen, Melanie P., et al.
Publicado: (2022)

Sustained minimal residual disease negativity in newly diagnosed multiple myeloma and the impact of daratumumab in MAIA and ALCYONE
por: San-Miguel, Jesus, et al.
Publicado: (2022)

OAB-029: Single-cell transcriptomic analysis reveals reduction of cytotoxic NK cells in a subset of newly diagnosed multiple myeloma patients impacting outcome after daratumumab therapy
por: Tahri, Sabrin, et al.
Publicado: (2022)

Pembrolizumab for patients with leptomeningeal metastasis from solid tumors: efficacy, safety, and cerebrospinal fluid biomarkers
por: Naidoo, Jarushka, et al.
Publicado: (2021)

Daratumumab, lenalidomide, and dexamethasone in relapsed/refractory myeloma: a cytogenetic subgroup analysis of POLLUX
por: Kaufman, Jonathan L., et al.
Publicado: (2020)

Cannot write session to /tmp/vufind_sessions/sess_kok1vjfb24ucjnlulsjigorkme